Coya Therapeutics (COYA) vs MAIA Biotechnology (MAIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MAIA Biotechnology (MAIA) has outperformed Coya Therapeutics (COYA) over the past year, gaining 21.7% versus a loss of 50.7%. Coya Therapeutics is the larger company by market cap ($69.2 million vs $68.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | MAIA |
|---|---|---|
| Share price | $2.95 | $1.11 |
| Market cap | $69.20M | $68.54M |
| 1-day change | -1.01% | -2.63% |
| YTD return | -49.14% | -27.45% |
| 1-year return | -50.67% | +21.71% |
| EPS (TTM) | $-1.39 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.95M | — |
| Revenue growth (YoY) | +123.57% | — |
| Net income (latest FY) | $-21.23M | $-22.40M |
| Operating margin | -283.87% | — |
| Net margin | -267.14% | — |
| 52-week high | $6.62 | $3.19 |
| 52-week low | $2.72 | $0.895 |
| Distance from 52-week high | -55.44% | -65.20% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +415.59% | +981.08% |
| Average volume | 149.18K | 524.29K |
| Shares outstanding | 23.46M | 61.75M |
| Employees | 8 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MAIA has outperformed COYA by 72.4 percentage points over the past year.
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
COYA vs MAIA FAQ
Which is bigger, Coya Therapeutics or MAIA Biotechnology?
Coya Therapeutics (COYA) is larger, with a market capitalization of $69.20M compared with $68.54M for MAIA Biotechnology (MAIA).
Which stock has performed better over the past year, COYA or MAIA?
MAIA returned +21.71% over the past 12 months, compared with -50.67% for COYA (price return, excluding dividends). Past performance does not predict future results.
Are Coya Therapeutics and MAIA Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.